Published in Haematologica on April 04, 2012
Genetic Association of Hematopoietic Stem Cell Transplantation Outcome beyond Histocompatibility Genes. Front Immunol (2017) 0.75
Targeting the Human T-Cell Inducible COStimulator Molecule with a Monoclonal Antibody Prevents Graft-vs-Host Disease and Preserves Graft vs Leukemia in a Xenograft Murine Model. Front Immunol (2017) 0.75
1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant (1995) 24.01
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature (1999) 5.76
IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol (1997) 4.52
A biomarker panel for acute graft-versus-host disease. Blood (2008) 3.83
Acute graft-versus-host disease: from the bench to the bedside. Blood (2009) 2.24
Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med (2010) 2.08
New perspectives on the biology of acute GVHD. Bone Marrow Transplant (2009) 1.40
Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med (2007) 1.40
Gene expression changes in peripheral blood mononuclear cells from multiple sclerosis patients undergoing beta-interferon therapy. J Neurol Sci (2007) 1.31
CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol (2006) 1.26
ICOS and CD28 reversely regulate IL-10 on re-activation of human effector T cells with mature dendritic cells. Eur J Immunol (2002) 1.19
Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med (2011) 1.15
Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am (2010) 1.10
Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol Blood Marrow Transplant (2008) 1.04
Opposing effects of anti-activation-inducible lymphocyte-immunomodulatory molecule/inducible costimulator antibody on the development of acute versus chronic graft-versus-host disease. J Immunol (2001) 1.00
Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant (2009) 0.91
Biomarkers of immune activation to screen for severe, acute GVHD. Bone Marrow Transplant (2010) 0.89
A preliminary gene expression profile of acute graft-versus-host disease. Cell Transplant (2008) 0.88
The use of monoclonal antibodies for the treatment of graft-versus-host disease following allogeneic stem cell transplantation. Expert Opin Biol Ther (2011) 0.85
Advances in the clinical management of GVHD. Best Pract Res Clin Haematol (2008) 0.81
TWNFI--a transductive neuro-fuzzy inference system with weighted data normalization for personalized modeling. Neural Netw (2006) 0.78
Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol (2010) 3.26
Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood (2003) 2.56
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41
Spontaneous intracranial hypotension syndrome: a novel speculative physiopathological hypothesis and a novel patch method in a series of 28 consecutive patients. J Neurosurg (2010) 2.38
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med (2016) 2.36
The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem (2004) 2.36
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study. Haematologica (2008) 2.29
Pigmented Bowen's disease mimicking cutaneous melanoma: clinical and dermoscopic aspects. Dermatol Surg (2004) 2.29
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol (2010) 2.27
Cigarette smoke-induced neurogenic inflammation is mediated by alpha,beta-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest (2008) 2.20
The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol (2005) 2.19
CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood (2003) 1.99
Diagnostic value of endomyocardial biopsy guided by electroanatomic voltage mapping in arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc Electrophysiol (2008) 1.98
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica (2008) 1.97
Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. J Clin Oncol (2006) 1.81
MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol (2008) 1.72
Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol (2009) 1.67
Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant (2011) 1.66
Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. Leuk Lymphoma (2006) 1.64
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. Mod Pathol (2010) 1.52
Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene (2005) 1.51
Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica (2002) 1.49
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma. Leuk Lymphoma (2011) 1.48
Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients. Leuk Res (2004) 1.48
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood (2007) 1.47
Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis. Arch Dermatol (2010) 1.46
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol (2014) 1.44
Clinically and dermoscopically featureless melanoma: when prevention fails. J Am Acad Dermatol (2002) 1.41
Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease. Leuk Lymphoma (2011) 1.39
The role of estrogens in melanoma and skin cancer. Carcinogenesis (2009) 1.38
Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer (2004) 1.35
Dermoscopy for "true" amelanotic melanoma: a clinical dermoscopic-pathologic case study. J Am Acad Dermatol (2006) 1.33
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol (2011) 1.32
Scoring of collagen organization in healthy and diseased human dermis by multiphoton microscopy. J Biophotonics (2010) 1.30
Sinonasal undifferentiated carcinoma, nasopharyngeal-type undifferentiated carcinoma, and keratinizing and nonkeratinizing squamous cell carcinoma express different cytokeratin patterns. Am J Surg Pathol (2002) 1.27
The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol (2011) 1.27
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. Blood (2013) 1.24
Vulvar basal cell carcinoma: retrospective study and review of literature. Gynecol Oncol (2005) 1.23
Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions. Hum Pathol (2009) 1.22
Melanomas that failed dermoscopic detection: a combined clinicodermoscopic approach for not missing melanoma. Dermatol Surg (2007) 1.17
Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol (2005) 1.16
Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res (2009) 1.16
IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia. Br J Haematol (2006) 1.15
Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer (2003) 1.15
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. Leuk Lymphoma (2010) 1.14
Dermoscopy in pigmented squamous cell carcinoma. J Cutan Med Surg (2009) 1.10
Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. Clin Cancer Res (2010) 1.10
Images in clinical medicine. Plantar melanoma--a false vegetant wart. N Engl J Med (2006) 1.09
Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. Haematologica (2008) 1.09
Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. Clin Cancer Res (2013) 1.09
CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. Int J Cancer (2004) 1.07
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood (2012) 1.07
The food contaminants bisphenol A and 4-nonylphenol act as agonists for estrogen receptor alpha in MCF7 breast cancer cells. Endocrine (2003) 1.07
Increase in FOXP3+ regulatory T cells in GVHD skin biopsies is associated with lower disease severity and treatment response. Biol Blood Marrow Transplant (2009) 1.07
Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. Epigenetics (2011) 1.05
Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br J Haematol (2005) 1.04
False "melanocytic" parameters shown by pigmented seborrheic keratoses: a finding which is not uncommon in dermoscopy. Dermatol Surg (2002) 1.04
Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer (2008) 1.03
Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: a GITMO study. Ann Hematol (2012) 1.02
The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor α-mediated signaling in cancer cells and in cardiomyocytes. PLoS One (2011) 1.01
CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. Hematol Oncol (2009) 1.01
Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma. J Pathol (2006) 1.00
High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. Br J Haematol (2014) 1.00
Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol (2007) 1.00
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res (2013) 0.98
Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol (2009) 0.98
Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies. Biol Blood Marrow Transplant (2012) 0.98
BRAFV600E detection in melanoma is highly improved by COLD-PCR. Clin Chim Acta (2011) 0.98
Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism. Basic Clin Pharmacol Toxicol (2007) 0.97
β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines. Lab Invest (2013) 0.97
Emerging role of Notch signaling in epidermal differentiation and skin cancer. Cancer Biol Ther (2009) 0.97
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res (2005) 0.97
Multiparametric analysis of cell-free DNA in melanoma patients. PLoS One (2012) 0.97
Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. Br J Haematol (2013) 0.96
Immediate local and regional recurrence after the excision of a polypoid melanoma: tumor dormancy or tumor activation? Dermatol Surg (2003) 0.96
Circulating cell-free DNA in plasma of melanoma patients: qualitative and quantitative considerations. Clin Chim Acta (2011) 0.96
Spectral morphological analysis of skin lesions with a polarization multispectral dermoscope. Opt Express (2013) 0.96
Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch (2014) 0.96
Keratinocyte growth factor receptors. Dermatol Clin (2007) 0.95
Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. Genes Chromosomes Cancer (2005) 0.95
CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood (2008) 0.94
Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology. Virchows Arch (2009) 0.93
Dermoscopic features of mucosal melanosis. Dermatol Surg (2004) 0.93
Giant melanoma displaying gross features reproducing parameters seen on dermoscopy. Dermatol Surg (2002) 0.93
Expression of Notch-1 and alteration of the E-cadherin/beta-catenin cell adhesion complex are observed in primary cutaneous neuroendocrine carcinoma (Merkel cell carcinoma). Mod Pathol (2009) 0.92
Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res (2013) 0.92